Voquezna

Erosive Esophagitis

Voquezna is used to heal all grades of erosive esophagitis, which is inflammation and damage to the lining of the esophagus caused by stomach acid. It is also used to maintain this healing and to provide relief from the heartburn symptoms associated with the condition.

Gastroesophageal Reflux Disease (GERD)

This medication is used to treat adults with non-erosive GERD. This is a condition where stomach acid flows back into the esophagus and causes symptoms like heartburn, even if the esophagus does not show visible signs of damage.

Helicobacter pylori Infection

Voquezna is used in combination with specific antibiotics to treat H. pylori infection in adults. This bacterial infection is a common cause of stomach ulcers. Depending on the treatment plan, it may be used in two ways:

• Triple Therapy: Used in combination with the antibiotics amoxicillin and clarithromycin.
• Dual Therapy: Used in combination with the antibiotic amoxicillin alone.

Mechanism of Action

Voquezna contains the active ingredient vonoprazan, which belongs to a class of medications known as potassium-competitive acid blockers (PCABs). It works by targeting the proton pumps in the stomach, which are the enzymes responsible for secreting stomach acid.

Unlike some other acid-reducing medications, Voquezna binds directly to these pumps and blocks them from releasing acid into the stomach. This process happens quickly and provides long-lasting suppression of acid production.

How It Helps the Body

By significantly lowering the amount of acid in the stomach, Voquezna helps with several conditions:

• Healing the Esophagus: Reducing acid allows the lining of the esophagus to heal from damage caused by acid reflux, a condition known as erosive esophagitis.
• Managing GERD: It helps relieve symptoms like heartburn by preventing excess acid from backing up into the food pipe.
• Treating Infections: When used to treat H. pylori infections, lowering stomach acid creates an environment where antibiotics can work more effectively to eliminate the bacteria.

Common Side Effects

Many people using Voquezna experience mild side effects. These may include:

• Stomach pain or discomfort
• Diarrhea or constipation
• Nausea
• Gas (flatulence)
• Headache
• Cold-like symptoms, such as a sore throat or stuffy nose
• Urinary tract infections

Serious Side Effects

While less common, Voquezna can cause serious health issues. Contact a healthcare provider immediately if you experience:

• Severe diarrhea: Watery or bloody stools, stomach cramps, and fever, which may indicate a Clostridioides difficile (C. diff) infection.
• Kidney problems: Signs may include changes in urination, blood in the urine, or swelling in the legs and feet.
• Low magnesium levels: Symptoms can include seizures, dizziness, irregular heartbeat, jitteriness, or muscle spasms.
• Bone fractures: Long-term use or high doses may increase the risk of hip, wrist, or spine fractures.
• Lupus erythematosus: New or worsening joint pain or a skin rash on the cheeks or arms that worsens in the sun.

Long-Term Use Considerations

Using this medication for a long period (typically over three years) may lead to a vitamin B12 deficiency. Additionally, long-term use has been associated with the development of fundic gland polyps, which are small growths in the lining of the stomach.

Serious Allergic and Skin Reactions

Some people may experience severe allergic reactions or serious skin conditions while taking this medication. Symptoms of a serious reaction can include rash, swelling, or difficulty breathing. Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, have been reported with the use of this class of medication.

Kidney Inflammation

Voquezna may cause a condition called acute tubulointerstitial nephritis, which is an inflammation of the kidneys. This can happen at any time during treatment and may lead to kidney failure if not addressed.

Severe Diarrhea

Like other medications that reduce stomach acid, Voquezna may increase the risk of severe diarrhea caused by an infection called Clostridioides difficile. This condition should be considered if watery stools, stomach pain, or fever develop and do not go away.

Bone Fractures

Using acid-blocking medications for a long time (usually a year or more) may increase the risk of fractures in the hip, wrist, or spine. This risk is generally higher for individuals taking high doses or those who already have osteoporosis.

Nutritional and Electrolyte Changes

• Magnesium levels: Long-term use may lead to low magnesium levels in the blood (hypomagnesemia). This can cause tremors, abnormal heart rhythms, or seizures. In some cases, magnesium supplementation or stopping the medication may be necessary.
• Vitamin B12 deficiency: Taking acid-suppressing medicine daily for a long period (typically more than three years) may make it harder for the body to absorb vitamin B12, potentially leading to a deficiency.

Drug Interactions

Voquezna can affect how the body absorbs other medicines that require stomach acid to work properly. It must not be used with medications containing rilpivirine, which is used to treat HIV. It is important to discuss all current medications with a healthcare provider to avoid potentially serious interactions.

Masking Other Conditions

If symptoms improve while taking Voquezna, it does not necessarily mean that more serious conditions, such as stomach cancer, are not present. Further medical evaluation may be needed if symptoms persist or return after treatment.

Pregnancy

There are no adequate studies on the use of Voquezna (vonoprazan) in pregnant women to determine drug-associated risks. In animal studies, high doses of vonoprazan were shown to potentially affect fetal development, including bone growth. Because human data is limited, the potential risk to a fetus is unknown.

If Voquezna is used as part of a combination pack, such as the Dual Pak or Triple Pak, the safety profiles of the other medications must also be considered. For example, clarithromycin is generally avoided during pregnancy unless there are no other suitable treatment options.

Breastfeeding

It is not known if vonoprazan passes into human breast milk or if it has any effect on a nursing child. Animal studies have indicated that the drug is present in the milk of lactating rats. Due to the potential for adverse reactions in the infant, patients should discuss with their healthcare provider whether to continue breastfeeding or discontinue the medication while being treated.

Dosage Forms

Voquezna is available in the following oral forms:

• Tablets: Vonoprazan is supplied as a tablet to be taken by mouth.
• Combination Packs: Voquezna is also available in convenience packs for treating specific conditions. These include a dual pack containing vonoprazan tablets and amoxicillin capsules, and a triple pack containing vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets.

FDA Approval Status

Voquezna was approved by the U.S. Food and Drug Administration (FDA) as the first medication in a class known as potassium-competitive acid blockers (PCABs). It is approved for use in adults to manage conditions related to excess stomach acid and bacterial infections.

Approved Indications

The FDA has approved Voquezna for several specific indications:

• Erosive Esophagitis: It is used for the healing of all grades of erosive esophagitis and to maintain that healing.
• Heartburn Relief: It is indicated for the relief of heartburn associated with erosive esophagitis.
• H. pylori Infection: It is approved for the treatment of Helicobacter pylori infection. For this use, it is administered in combination with antibiotics.

Regulatory Packaging

For the treatment of H. pylori, the FDA has approved specific co-packaged products to facilitate the multi-drug regimen:

• Voquezna Dual Pak: Contains vonoprazan and amoxicillin.
• Voquezna Triple Pak: Contains vonoprazan, amoxicillin, and clarithromycin.

These combination packs are regulated to ensure patients receive the correct dosages of each component required to eradicate the infection.

Factors Influencing Cost

The amount you pay for Voquezna can vary based on several elements:

• Insurance Coverage: Your out-of-pocket costs will depend on your specific health insurance plan, its formulary, and your copay or coinsurance requirements.
• Pharmacy Choice: Prices may differ between retail pharmacies, mail-order services, and specialty pharmacies.
• Medication Type: Voquezna is available as individual tablets and as part of combination packs for treating H. pylori infections, which may have different pricing structures.

Generic Availability

Currently, there is no generic version of vonoprazan (the active ingredient in Voquezna) available in the United States. Brand-name medications typically cost more than generics because they are newer and protected by patents.

Financial Assistance Programs

The manufacturer of Voquezna may offer financial assistance programs, such as savings cards or coupons, for patients who meet certain eligibility criteria. These programs can help reduce the cost for those with commercial insurance. It is recommended to check the manufacturer's website or speak with a pharmacist for the most current savings options and eligibility requirements.